Your browser doesn't support javascript.
loading
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
Huang, Yunda; Naidoo, Logashvari; Zhang, Lily; Carpp, Lindsay N; Rudnicki, Erika; Randhawa, April; Gonzales, Pedro; McDermott, Adrian; Ledgerwood, Julie; Lorenzo, Margarita M Gomez; Burns, David; DeCamp, Allan; Juraska, Michal; Mascola, John; Edupuganti, Srilatha; Mgodi, Nyaradzo; Cohen, Myron; Corey, Lawrence; Andrew, Philip; Karuna, Shelly; Gilbert, Peter B; Mngadi, Kathryn; Lazarus, Erica.
Affiliation
  • Huang Y; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Department of Global Health, University of Washington, Seattle, WA,
  • Naidoo L; HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.
  • Zhang L; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Carpp LN; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Rudnicki E; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Randhawa A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Gonzales P; Asociacion Civil Impacta Salud y Educacion, Lima, Perú.
  • McDermott A; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Ledgerwood J; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Lorenzo MMG; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America.
  • Burns D; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America.
  • DeCamp A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Juraska M; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Mascola J; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Edupuganti S; Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, United States of America.
  • Mgodi N; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
  • Cohen M; Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, United States of America; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, United States of America.
  • Corey L; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, WA, United States of America.
  • Andrew P; Family Health International, Durham, NC, United States of America.
  • Karuna S; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Gilbert PB; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Department of Biostatistics, University of Washington, Seattle, WA,
  • Mngadi K; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Lazarus E; Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
EBioMedicine ; 64: 103203, 2021 Feb.
Article in En | MEDLINE | ID: mdl-33493795
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Infections / HIV-1 / Anti-HIV Agents / Antibodies, Neutralizing / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: EBioMedicine Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Infections / HIV-1 / Anti-HIV Agents / Antibodies, Neutralizing / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: EBioMedicine Year: 2021 Type: Article